Table 2. . Top ten associations by study with p < 5 × 10-5.
| Study | Year | Dosing: fixed or flexible? | Efficacy measure | Medication | Primary findings† | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| Gene | Polymorphism | p (or q)-value | ||||||
| Lavedan et al. | (2009) | Fixed | >20% improvement in PANSS total score | Iloperidone | NUDT9P1 | rs4528226 | 7.8 × 10-7 | [9] |
| Iloperidone | TNR | rs875326 | 2.1 × 10-5 | |||||
| Ikeda et al. | (2010) | Flexible | PANSS total score | Risperidone | ATP2B2 | rs2289273 | 1.60 × 10-5 | [10] |
| McClay et al. | (2011) | Flexible | PANSS positive, negative and excitement scores | Ziprasidone | Intergenic | rs17390445 | 9.8 × 10-8 | [11] |
| Ziprasidone | Intergenic | rs888219 | 2.3 × 10-7 | |||||
| Risperidone | ANKS1B | rs7968606 | 3.2 × 10-7 | |||||
| Olanzapine | CNTNAP5 | rs17727261 | 5.4 × 10-7 | |||||
| Risperidone | Intergenic | rs11722719 | 5.4 × 10-7 | |||||
| Olanzapine | Intergenic | rs10888501 | 1.4 × 10-6 | |||||
| Olanzapine | Intergenic | rs1040994 | 1.8 × 10-6 | |||||
| Olanzapine | Intergenic | rs10484256 | 2.7 × 10-6 | |||||
| Olanzapine | Intergenic | rs7635839 | 3.0 × 10-6 | |||||
| Risperidone | Intergenic | rs12526186 | 3.1 × 10-6 | |||||
| Clark et al. | (2013) | Flexible | CGI-S improvement | Olanzapine | Intergenic | rs8050896 | 3.9 × 10-8 | [12] |
| Risperidone | ATP1A2 | rs6688363 | 1.6 × 10-7 | |||||
| Risperidone | Intergenic | rs7395555 | 2.0 × 10-7 | |||||
| Risperidone | TNFRSF11A | rs2980976 | 3.0 × 10-7 | |||||
| Risperidone | PPA2 | rs2636697 | 3.7 × 10-7 | |||||
| PGI improvement | Olanzapine | PDE4D | rs17382202 | 4.2 × 10-8 | ||||
| Quetiapine | SPOPL | rs10170310 | 1.0 × 10-7 | |||||
| Quetiapine | PDE4D | rs17742120 | 1.6 × 10-7 | |||||
| Quetiapine | PDE4D | rs2164660 | 1.9 × 10-7 | |||||
| Risperidone | TJP1 | rs711355 | 2.3 × 10-7 | |||||
| Drago et al. | (2014) | Flexible | PANSS total score improvement | Haloperidol | Intergenic | rs7912580 | 1.4 × 10-6 | [13] |
| EIF2AK4 | rs2412459 | 8.9 × 10-6 | ||||||
| Stevenson et al. | (2016) | Flexible | BPRS total score | Primarily risperidone | GRID2 | rs9307122 | 1.1 × 10-8 | [14] |
| GRID2 | rs1875705 | 1.1 × 10-8 | ||||||
| APTX | rs3824457 | 1.3 × 10-6 | ||||||
| Intergenic | rs1992525 | 1.4 × 10-6 | ||||||
| GRID2 | rs994011 | 1.6 × 10-6 | ||||||
| MDGA1 | rs804855 | 1.8 × 10-6 | ||||||
| SMU1 | rs2274766 | 2.5 × 10-6 | ||||||
| LOC727677 (CASC8) | rs687279 | 2.9 × 10-6 | ||||||
| Intergenic | rs2288687 | 4.8 × 10-6 | ||||||
| NPY | rs16100 | 5.2 × 10-6 | ||||||
| Sacchetti et al. | (2016) | Flexible | PANSS positive score | Risperidone | GRM7 | rs2133450 | 4.3 × 10-8 | [15] |
| Li et al. | (2017) | Flexible | CGI-S, PANSS total score | Paliperidone | ADCK1 | rs56240334 | 8.0 × 10-8 | [16] |
| Intergenic | rs12915820 | 1.2 × 10-7 | ||||||
| Yu et al. | (2018) | Flexible | PANSS total score | Aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, haloperidol, perphenazine | MEGF10 | rs72790443 | 1.4 × 10-9 | [20] |
| SLC1A1 | rs1471786 | 2.3 × 10-9 | ||||||
| PCDH7 | rs9291547 | 3.2 × 10-9 | ||||||
| CNTNAP5 | rs12711680 | 2.1 × 10-8 | ||||||
| TNIK | rs6444970 | 4.9 × 10-8 | ||||||
| PCDH7 | rs77685948 | 6.7 × 10-8 | ||||||
| SPATA6L | rs301440 | 2.0 × 10-7 | ||||||
| MEGF10 | rs150192045 | 1.7 × 10-7 | ||||||
| CNTNAP5 | rs4848939 | 3.8 × 10-7 | ||||||
| NBEA | rs9544382 | 9.4 × 10-6 | ||||||
| Li et al. | (2018) | Fixed | PANSS total score | Lurasidone | KCNK9 | rs4736253 | 4.8 × 10-8 | [18] |
| DYNC2H1 | rs10895475 | 2.4 × 10-7 | ||||||
| CTNNA2 | rs10180106 | 4.9 × 10-7 | ||||||
| STXBP5L | rs511841 | 2.6 × 10-7 | ||||||
†Genome-wide significant findings (as defined by the source publications) are bolded.
BPRS: Brief Psychiatric Rating Scale; CGI-S: Clinical Global Impression - Severity; PANSS: Positive and negative symptom scale; PGI: Patient global improvement.